| Trial ID: | L2010 |
| Source ID: | NCT00518427
|
| Associated Drug: |
Insulin Glargine
|
| Title: |
Evaluate Quality of Life in Type 2 Diabetes, Before and After Change to Insuline Glargine
|
| Acronym: |
QoL
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Type 2
|
| Interventions: |
DRUG: Insulin Glargine
|
| Outcome Measures: |
Primary: The fear of hypoglycaemia scale (HFS), before the switch to insulin glargine and at 3 and 9 months of follow up.|12 - Item Well-Being Questionnaaire (WBQ12), before the switch to insulin glargine and at 3 and 9 months of follow up.|Glycaemic controll will be asessed by HbA1c values, week 12 and week 40 | Secondary: Incidence of symptomatic hypoglycemia and severe hypoglycemia, sreening to follow-up phases
|
| Sponsor/Collaborators: |
Sponsor: Sanofi
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE4
|
| Enrollment: |
26
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: NON_RANDOMIZED|Intervention Model: SINGLE_GROUP|Masking: NONE|Primary Purpose: TREATMENT
|
| Start Date: |
2005-10
|
| Completion Date: |
2008-03
|
| Results First Posted: |
|
| Last Update Posted: |
2009-12-07
|
| Locations: |
Sanofi-Aventis Administrative Office, Bromma, Sweden
|
| URL: |
https://clinicaltrials.gov/show/NCT00518427
|
